Global Brain Tumor Diagnosis and Treatments Market

Brain Tumor Diagnosis and Treatments Comprehensive Study by Type (Primary Brain Tumor (Meningioma, Gliomas, Astrocytomas, Pituitary Tumors, Other Primary Brain Tumors), Secondary Brain Tumor), Application (Hospital, Medical center), Drug Type (Temozolomide, Carmustine, Cisplatin, Bevacizumab, Geftinib, Erlotinib), Diagnosis Testing (PET-CT scan, MRI, CT scan, EEG, Molecular testing, Others), Treatment Type (Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy, Immunotherapy), Type of Brain Tumor (Anaplastic astrocytoma, Anaplastic oligodendroglioma, Low-grade (diffuse) astrocytoma, Ependymoma, Glioblastoma, Oligodendroglioma) Players and Region - Global Market Outlook to 2027

Brain Tumor Diagnosis and Treatments Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 8.65%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
According to the National Brain Tumour Society, an estimated 688,000 plus people are living with a primary brain or Central Nervous System (CNS) tumor. Brain tumors generally occur in supportive brain tissues. The exact cause of brain tumor is not yet known, and it can occur in any age group. A brain tumor is an abnormal and uncontrolled proliferation of cells in the brain. It can be benign or malignant. Brain tumor arises from brain tissue and rarely spreads. The tumor eventually compress and damage other structures in the brain. Increase in the incidence rate of brain tumor has fuelled the demand for effective treatment for Brain Tumour Diagnosis & Treatment market. Many products related to novel drug delivery technologies for the treatment for Brain Tumour are still lined up for FDA approval.

AttributesDetails
Study Period2017-2027
Base Year2021
Current Value (2021)USD 2.89 Million
UnitValue (USD Million)
Key Companies ProfiledAstraZeneca (United Kingdom), Carestream Health (United States), GE Healthcare (United States), Hitachi, Ltd. (Japan), Merck KGaA (United States), Koninklijke Philips N.V (Netherlands), Pfizer, Inc. (United States), Shimadzu Corporation (Japan), Siemens Healthineers (Germany), Dr. Reddy’s Laboratories Ltd (India) and iTeos Therapeutics SA (Belgium)


According to AMA, the market for Brain Tumor Diagnosis and Treatments is expected to register a CAGR of 8.65% during the forecast period to 2027. This growth is primarily driven by Increase in the Number of Patients Suffering from Malignant Cancer, Technological Advancement Related to Brain Tumour Treatment, Growing Geriatric population & Increased Prevalence of Brain Tumor Patients and Increasing Consumer Awareness Regarding the Latest Technological Advancements in therapies, and medications..

Globally, a noticeable market trend is evident The launch of new technologies such as Sodium Magnetic Resonance imaging (23Na MRI), Chemical Exchange Saturation Transfer (CEST) and Positron Emission Tomography (PET), . The Diseases & Therapeutic Areas sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as AstraZeneca (United Kingdom), Carestream Health (United States), GE Healthcare (United States), Hitachi, Ltd. (Japan), Merck KGaA (United States), Koninklijke Philips N.V (Netherlands), Pfizer, Inc. (United States), Shimadzu Corporation (Japan), Siemens Healthineers (Germany), Dr. Reddy’s Laboratories Ltd (India) and iTeos Therapeutics SA (Belgium) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In January 2018, iTeos Therapeutics SA, a biotechnology company has developed Novel Cancer Immunotherapies from Pfizer to develop and commercialize, a highly selective, clinical-stage IDO1 inhibitor. and Pfizer initiated a Phase 1 clinical study for a single agent in patients with malignant gliomas (brain cancer), an area of significant unmet need, based on brain penetration of the compound.

Market Drivers
  • Increase in the Number of Patients Suffering from Malignant Cancer
  • Technological Advancement Related to Brain Tumour Treatment
  • Growing Geriatric population & Increased Prevalence of Brain Tumor Patients
  • Increasing Consumer Awareness Regarding the Latest Technological Advancements in therapies, and medications.

Market Trend
  • The launch of new technologies such as Sodium Magnetic Resonance imaging (23Na MRI), Chemical Exchange Saturation Transfer (CEST) and Positron Emission Tomography (PET),
  • Detection of Brain tumor in Multicenter Clinical Experimental Settings
  • Advancement in Technology Stimulating the Proficiency of Diagnosis

Restraints
  • Availability of only a few brain cancer-specific drugs and their high cost
  • High Expense associated with the Brain Tumor Diagnosis and Treatments

Opportunities
Increasing Brain Cancer Patients, R & D Investment activities and New Innovative Drugs in the Pipeline

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Brain Tumor Diagnosis and Treatments Study Sheds Light on
— The Brain Tumor Diagnosis and Treatments Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Brain Tumor Diagnosis and Treatments industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Brain Tumor Diagnosis and Treatments industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Primary Brain Tumor (Meningioma, Gliomas, Astrocytomas, Pituitary Tumors, Other Primary Brain Tumors)
  • Secondary Brain Tumor
By Application
  • Hospital
  • Medical center
By Drug Type
  • Temozolomide
  • Carmustine
  • Cisplatin
  • Bevacizumab
  • Geftinib
  • Erlotinib

By Diagnosis Testing
  • PET-CT scan
  • MRI
  • CT scan
  • EEG
  • Molecular testing
  • Others

By Treatment Type
  • Surgery
  • Radiation Therapy
  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy

By Type of Brain Tumor
  • Anaplastic astrocytoma
  • Anaplastic oligodendroglioma
  • Low-grade (diffuse) astrocytoma
  • Ependymoma
  • Glioblastoma
  • Oligodendroglioma

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the Number of Patients Suffering from Malignant Cancer
      • 3.2.2. Technological Advancement Related to Brain Tumour Treatment
      • 3.2.3. Growing Geriatric population & Increased Prevalence of Brain Tumor Patients
      • 3.2.4. Increasing Consumer Awareness Regarding the Latest Technological Advancements in therapies, and medications.
    • 3.3. Market Challenges
      • 3.3.1. Effective Drug Discovery & Patient selection, trial end-point analyses, and the Different Trial Parameters
    • 3.4. Market Trends
      • 3.4.1. The launch of new technologies such as Sodium Magnetic Resonance imaging (23Na MRI), Chemical Exchange Saturation Transfer (CEST) and Positron Emission Tomography (PET),
      • 3.4.2. Detection of Brain tumor in Multicenter Clinical Experimental Settings
      • 3.4.3. Advancement in Technology Stimulating the Proficiency of Diagnosis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Brain Tumor Diagnosis and Treatments, by Type, Application, Drug Type, Diagnosis Testing, Treatment Type, Type of Brain Tumor and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Brain Tumor Diagnosis and Treatments (Value)
      • 5.2.1. Global Brain Tumor Diagnosis and Treatments by: Type (Value)
        • 5.2.1.1. Primary Brain Tumor (Meningioma, Gliomas, Astrocytomas, Pituitary Tumors, Other Primary Brain Tumors)
        • 5.2.1.2. Secondary Brain Tumor
      • 5.2.2. Global Brain Tumor Diagnosis and Treatments by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Medical center
      • 5.2.3. Global Brain Tumor Diagnosis and Treatments by: Drug Type (Value)
        • 5.2.3.1. Temozolomide
        • 5.2.3.2. Carmustine
        • 5.2.3.3. Cisplatin
        • 5.2.3.4. Bevacizumab
        • 5.2.3.5. Geftinib
        • 5.2.3.6. Erlotinib
      • 5.2.4. Global Brain Tumor Diagnosis and Treatments by: Diagnosis Testing (Value)
        • 5.2.4.1. PET-CT scan
        • 5.2.4.2. MRI
        • 5.2.4.3. CT scan
        • 5.2.4.4. EEG
        • 5.2.4.5. Molecular testing
        • 5.2.4.6. Others
      • 5.2.5. Global Brain Tumor Diagnosis and Treatments by: Treatment Type (Value)
        • 5.2.5.1. Surgery
        • 5.2.5.2. Radiation Therapy
        • 5.2.5.3. Targeted Therapy
        • 5.2.5.4. Chemotherapy
        • 5.2.5.5. Immunotherapy
      • 5.2.6. Global Brain Tumor Diagnosis and Treatments by: Type of Brain Tumor (Value)
        • 5.2.6.1. Anaplastic astrocytoma
        • 5.2.6.2. Anaplastic oligodendroglioma
        • 5.2.6.3. Low-grade (diffuse) astrocytoma
        • 5.2.6.4. Ependymoma
        • 5.2.6.5. Glioblastoma
        • 5.2.6.6. Oligodendroglioma
      • 5.2.7. Global Brain Tumor Diagnosis and Treatments Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
  • 6. Brain Tumor Diagnosis and Treatments: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Carestream Health (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GE Healthcare (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Hitachi, Ltd. (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck KGaA (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Koninklijke Philips N.V (Netherlands)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Shimadzu Corporation (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Siemens Healthineers (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Dr. Reddy’s Laboratories Ltd (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. ITeos Therapeutics SA (Belgium)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Brain Tumor Diagnosis and Treatments Sale, by Type, Application, Drug Type, Diagnosis Testing, Treatment Type, Type of Brain Tumor and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Brain Tumor Diagnosis and Treatments (Value)
      • 7.2.1. Global Brain Tumor Diagnosis and Treatments by: Type (Value)
        • 7.2.1.1. Primary Brain Tumor (Meningioma, Gliomas, Astrocytomas, Pituitary Tumors, Other Primary Brain Tumors)
        • 7.2.1.2. Secondary Brain Tumor
      • 7.2.2. Global Brain Tumor Diagnosis and Treatments by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Medical center
      • 7.2.3. Global Brain Tumor Diagnosis and Treatments by: Drug Type (Value)
        • 7.2.3.1. Temozolomide
        • 7.2.3.2. Carmustine
        • 7.2.3.3. Cisplatin
        • 7.2.3.4. Bevacizumab
        • 7.2.3.5. Geftinib
        • 7.2.3.6. Erlotinib
      • 7.2.4. Global Brain Tumor Diagnosis and Treatments by: Diagnosis Testing (Value)
        • 7.2.4.1. PET-CT scan
        • 7.2.4.2. MRI
        • 7.2.4.3. CT scan
        • 7.2.4.4. EEG
        • 7.2.4.5. Molecular testing
        • 7.2.4.6. Others
      • 7.2.5. Global Brain Tumor Diagnosis and Treatments by: Treatment Type (Value)
        • 7.2.5.1. Surgery
        • 7.2.5.2. Radiation Therapy
        • 7.2.5.3. Targeted Therapy
        • 7.2.5.4. Chemotherapy
        • 7.2.5.5. Immunotherapy
      • 7.2.6. Global Brain Tumor Diagnosis and Treatments by: Type of Brain Tumor (Value)
        • 7.2.6.1. Anaplastic astrocytoma
        • 7.2.6.2. Anaplastic oligodendroglioma
        • 7.2.6.3. Low-grade (diffuse) astrocytoma
        • 7.2.6.4. Ependymoma
        • 7.2.6.5. Glioblastoma
        • 7.2.6.6. Oligodendroglioma
      • 7.2.7. Global Brain Tumor Diagnosis and Treatments Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Brain Tumor Diagnosis and Treatments: by Type(USD Million)
  • Table 2. Brain Tumor Diagnosis and Treatments Primary Brain Tumor (Meningioma, Gliomas, Astrocytomas, Pituitary Tumors, Other Primary Brain Tumors) , by Region USD Million (2016-2021)
  • Table 3. Brain Tumor Diagnosis and Treatments Secondary Brain Tumor , by Region USD Million (2016-2021)
  • Table 4. Brain Tumor Diagnosis and Treatments: by Application(USD Million)
  • Table 5. Brain Tumor Diagnosis and Treatments Hospital , by Region USD Million (2016-2021)
  • Table 6. Brain Tumor Diagnosis and Treatments Medical center , by Region USD Million (2016-2021)
  • Table 7. Brain Tumor Diagnosis and Treatments: by Drug Type(USD Million)
  • Table 8. Brain Tumor Diagnosis and Treatments Temozolomide , by Region USD Million (2016-2021)
  • Table 9. Brain Tumor Diagnosis and Treatments Carmustine , by Region USD Million (2016-2021)
  • Table 10. Brain Tumor Diagnosis and Treatments Cisplatin , by Region USD Million (2016-2021)
  • Table 11. Brain Tumor Diagnosis and Treatments Bevacizumab , by Region USD Million (2016-2021)
  • Table 12. Brain Tumor Diagnosis and Treatments Geftinib , by Region USD Million (2016-2021)
  • Table 13. Brain Tumor Diagnosis and Treatments Erlotinib , by Region USD Million (2016-2021)
  • Table 14. Brain Tumor Diagnosis and Treatments: by Diagnosis Testing(USD Million)
  • Table 15. Brain Tumor Diagnosis and Treatments PET-CT scan , by Region USD Million (2016-2021)
  • Table 16. Brain Tumor Diagnosis and Treatments MRI , by Region USD Million (2016-2021)
  • Table 17. Brain Tumor Diagnosis and Treatments CT scan , by Region USD Million (2016-2021)
  • Table 18. Brain Tumor Diagnosis and Treatments EEG , by Region USD Million (2016-2021)
  • Table 19. Brain Tumor Diagnosis and Treatments Molecular testing , by Region USD Million (2016-2021)
  • Table 20. Brain Tumor Diagnosis and Treatments Others , by Region USD Million (2016-2021)
  • Table 21. Brain Tumor Diagnosis and Treatments: by Treatment Type(USD Million)
  • Table 22. Brain Tumor Diagnosis and Treatments Surgery , by Region USD Million (2016-2021)
  • Table 23. Brain Tumor Diagnosis and Treatments Radiation Therapy , by Region USD Million (2016-2021)
  • Table 24. Brain Tumor Diagnosis and Treatments Targeted Therapy , by Region USD Million (2016-2021)
  • Table 25. Brain Tumor Diagnosis and Treatments Chemotherapy , by Region USD Million (2016-2021)
  • Table 26. Brain Tumor Diagnosis and Treatments Immunotherapy , by Region USD Million (2016-2021)
  • Table 27. Brain Tumor Diagnosis and Treatments: by Type of Brain Tumor(USD Million)
  • Table 28. Brain Tumor Diagnosis and Treatments Anaplastic astrocytoma , by Region USD Million (2016-2021)
  • Table 29. Brain Tumor Diagnosis and Treatments Anaplastic oligodendroglioma , by Region USD Million (2016-2021)
  • Table 30. Brain Tumor Diagnosis and Treatments Low-grade (diffuse) astrocytoma , by Region USD Million (2016-2021)
  • Table 31. Brain Tumor Diagnosis and Treatments Ependymoma , by Region USD Million (2016-2021)
  • Table 32. Brain Tumor Diagnosis and Treatments Glioblastoma , by Region USD Million (2016-2021)
  • Table 33. Brain Tumor Diagnosis and Treatments Oligodendroglioma , by Region USD Million (2016-2021)
  • Table 34. South America Brain Tumor Diagnosis and Treatments, by Country USD Million (2016-2021)
  • Table 35. South America Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 36. South America Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 37. South America Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 38. South America Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 39. South America Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 40. South America Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 41. Brazil Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 42. Brazil Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 43. Brazil Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 44. Brazil Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 45. Brazil Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 46. Brazil Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 47. Argentina Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 48. Argentina Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 49. Argentina Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 50. Argentina Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 51. Argentina Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 52. Argentina Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 53. Rest of South America Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 54. Rest of South America Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 55. Rest of South America Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 56. Rest of South America Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 57. Rest of South America Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 58. Rest of South America Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 59. Asia Pacific Brain Tumor Diagnosis and Treatments, by Country USD Million (2016-2021)
  • Table 60. Asia Pacific Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 61. Asia Pacific Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 62. Asia Pacific Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 63. Asia Pacific Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 64. Asia Pacific Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 65. Asia Pacific Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 66. China Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 67. China Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 68. China Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 69. China Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 70. China Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 71. China Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 72. Japan Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 73. Japan Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 74. Japan Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 75. Japan Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 76. Japan Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 77. Japan Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 78. India Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 79. India Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 80. India Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 81. India Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 82. India Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 83. India Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 84. South Korea Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 85. South Korea Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 86. South Korea Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 87. South Korea Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 88. South Korea Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 89. South Korea Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 90. Taiwan Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 91. Taiwan Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 92. Taiwan Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 93. Taiwan Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 94. Taiwan Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 95. Taiwan Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 96. Australia Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 97. Australia Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 98. Australia Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 99. Australia Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 100. Australia Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 101. Australia Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 102. Rest of Asia-Pacific Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 103. Rest of Asia-Pacific Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 104. Rest of Asia-Pacific Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 105. Rest of Asia-Pacific Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 106. Rest of Asia-Pacific Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 107. Rest of Asia-Pacific Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 108. Europe Brain Tumor Diagnosis and Treatments, by Country USD Million (2016-2021)
  • Table 109. Europe Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 110. Europe Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 111. Europe Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 112. Europe Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 113. Europe Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 114. Europe Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 115. Germany Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 116. Germany Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 117. Germany Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 118. Germany Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 119. Germany Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 120. Germany Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 121. France Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 122. France Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 123. France Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 124. France Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 125. France Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 126. France Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 127. Italy Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 128. Italy Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 129. Italy Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 130. Italy Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 131. Italy Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 132. Italy Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 133. United Kingdom Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 134. United Kingdom Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 135. United Kingdom Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 136. United Kingdom Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 137. United Kingdom Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 138. United Kingdom Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 139. Netherlands Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 140. Netherlands Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 141. Netherlands Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 142. Netherlands Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 143. Netherlands Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 144. Netherlands Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 145. Rest of Europe Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 146. Rest of Europe Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 147. Rest of Europe Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 148. Rest of Europe Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 149. Rest of Europe Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 150. Rest of Europe Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 151. MEA Brain Tumor Diagnosis and Treatments, by Country USD Million (2016-2021)
  • Table 152. MEA Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 153. MEA Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 154. MEA Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 155. MEA Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 156. MEA Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 157. MEA Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 158. Middle East Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 159. Middle East Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 160. Middle East Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 161. Middle East Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 162. Middle East Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 163. Middle East Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 164. Africa Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 165. Africa Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 166. Africa Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 167. Africa Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 168. Africa Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 169. Africa Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 170. North America Brain Tumor Diagnosis and Treatments, by Country USD Million (2016-2021)
  • Table 171. North America Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 172. North America Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 173. North America Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 174. North America Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 175. North America Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 176. North America Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 177. United States Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 178. United States Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 179. United States Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 180. United States Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 181. United States Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 182. United States Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 183. Canada Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 184. Canada Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 185. Canada Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 186. Canada Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 187. Canada Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 188. Canada Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 189. Mexico Brain Tumor Diagnosis and Treatments, by Type USD Million (2016-2021)
  • Table 190. Mexico Brain Tumor Diagnosis and Treatments, by Application USD Million (2016-2021)
  • Table 191. Mexico Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2016-2021)
  • Table 192. Mexico Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2016-2021)
  • Table 193. Mexico Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2016-2021)
  • Table 194. Mexico Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2016-2021)
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Brain Tumor Diagnosis and Treatments: by Type(USD Million)
  • Table 207. Brain Tumor Diagnosis and Treatments Primary Brain Tumor (Meningioma, Gliomas, Astrocytomas, Pituitary Tumors, Other Primary Brain Tumors) , by Region USD Million (2022-2027)
  • Table 208. Brain Tumor Diagnosis and Treatments Secondary Brain Tumor , by Region USD Million (2022-2027)
  • Table 209. Brain Tumor Diagnosis and Treatments: by Application(USD Million)
  • Table 210. Brain Tumor Diagnosis and Treatments Hospital , by Region USD Million (2022-2027)
  • Table 211. Brain Tumor Diagnosis and Treatments Medical center , by Region USD Million (2022-2027)
  • Table 212. Brain Tumor Diagnosis and Treatments: by Drug Type(USD Million)
  • Table 213. Brain Tumor Diagnosis and Treatments Temozolomide , by Region USD Million (2022-2027)
  • Table 214. Brain Tumor Diagnosis and Treatments Carmustine , by Region USD Million (2022-2027)
  • Table 215. Brain Tumor Diagnosis and Treatments Cisplatin , by Region USD Million (2022-2027)
  • Table 216. Brain Tumor Diagnosis and Treatments Bevacizumab , by Region USD Million (2022-2027)
  • Table 217. Brain Tumor Diagnosis and Treatments Geftinib , by Region USD Million (2022-2027)
  • Table 218. Brain Tumor Diagnosis and Treatments Erlotinib , by Region USD Million (2022-2027)
  • Table 219. Brain Tumor Diagnosis and Treatments: by Diagnosis Testing(USD Million)
  • Table 220. Brain Tumor Diagnosis and Treatments PET-CT scan , by Region USD Million (2022-2027)
  • Table 221. Brain Tumor Diagnosis and Treatments MRI , by Region USD Million (2022-2027)
  • Table 222. Brain Tumor Diagnosis and Treatments CT scan , by Region USD Million (2022-2027)
  • Table 223. Brain Tumor Diagnosis and Treatments EEG , by Region USD Million (2022-2027)
  • Table 224. Brain Tumor Diagnosis and Treatments Molecular testing , by Region USD Million (2022-2027)
  • Table 225. Brain Tumor Diagnosis and Treatments Others , by Region USD Million (2022-2027)
  • Table 226. Brain Tumor Diagnosis and Treatments: by Treatment Type(USD Million)
  • Table 227. Brain Tumor Diagnosis and Treatments Surgery , by Region USD Million (2022-2027)
  • Table 228. Brain Tumor Diagnosis and Treatments Radiation Therapy , by Region USD Million (2022-2027)
  • Table 229. Brain Tumor Diagnosis and Treatments Targeted Therapy , by Region USD Million (2022-2027)
  • Table 230. Brain Tumor Diagnosis and Treatments Chemotherapy , by Region USD Million (2022-2027)
  • Table 231. Brain Tumor Diagnosis and Treatments Immunotherapy , by Region USD Million (2022-2027)
  • Table 232. Brain Tumor Diagnosis and Treatments: by Type of Brain Tumor(USD Million)
  • Table 233. Brain Tumor Diagnosis and Treatments Anaplastic astrocytoma , by Region USD Million (2022-2027)
  • Table 234. Brain Tumor Diagnosis and Treatments Anaplastic oligodendroglioma , by Region USD Million (2022-2027)
  • Table 235. Brain Tumor Diagnosis and Treatments Low-grade (diffuse) astrocytoma , by Region USD Million (2022-2027)
  • Table 236. Brain Tumor Diagnosis and Treatments Ependymoma , by Region USD Million (2022-2027)
  • Table 237. Brain Tumor Diagnosis and Treatments Glioblastoma , by Region USD Million (2022-2027)
  • Table 238. Brain Tumor Diagnosis and Treatments Oligodendroglioma , by Region USD Million (2022-2027)
  • Table 239. South America Brain Tumor Diagnosis and Treatments, by Country USD Million (2022-2027)
  • Table 240. South America Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 241. South America Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 242. South America Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 243. South America Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 244. South America Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 245. South America Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 246. Brazil Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 247. Brazil Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 248. Brazil Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 249. Brazil Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 250. Brazil Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 251. Brazil Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 252. Argentina Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 253. Argentina Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 254. Argentina Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 255. Argentina Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 256. Argentina Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 257. Argentina Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 258. Rest of South America Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 259. Rest of South America Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 260. Rest of South America Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 261. Rest of South America Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 262. Rest of South America Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 263. Rest of South America Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 264. Asia Pacific Brain Tumor Diagnosis and Treatments, by Country USD Million (2022-2027)
  • Table 265. Asia Pacific Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 266. Asia Pacific Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 267. Asia Pacific Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 268. Asia Pacific Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 269. Asia Pacific Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 270. Asia Pacific Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 271. China Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 272. China Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 273. China Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 274. China Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 275. China Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 276. China Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 277. Japan Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 278. Japan Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 279. Japan Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 280. Japan Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 281. Japan Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 282. Japan Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 283. India Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 284. India Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 285. India Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 286. India Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 287. India Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 288. India Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 289. South Korea Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 290. South Korea Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 291. South Korea Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 292. South Korea Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 293. South Korea Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 294. South Korea Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 295. Taiwan Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 296. Taiwan Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 297. Taiwan Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 298. Taiwan Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 299. Taiwan Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 300. Taiwan Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 301. Australia Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 302. Australia Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 303. Australia Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 304. Australia Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 305. Australia Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 306. Australia Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 307. Rest of Asia-Pacific Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 308. Rest of Asia-Pacific Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 309. Rest of Asia-Pacific Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 310. Rest of Asia-Pacific Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 311. Rest of Asia-Pacific Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 312. Rest of Asia-Pacific Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 313. Europe Brain Tumor Diagnosis and Treatments, by Country USD Million (2022-2027)
  • Table 314. Europe Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 315. Europe Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 316. Europe Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 317. Europe Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 318. Europe Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 319. Europe Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 320. Germany Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 321. Germany Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 322. Germany Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 323. Germany Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 324. Germany Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 325. Germany Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 326. France Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 327. France Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 328. France Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 329. France Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 330. France Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 331. France Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 332. Italy Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 333. Italy Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 334. Italy Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 335. Italy Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 336. Italy Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 337. Italy Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 338. United Kingdom Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 339. United Kingdom Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 340. United Kingdom Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 341. United Kingdom Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 342. United Kingdom Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 343. United Kingdom Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 344. Netherlands Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 345. Netherlands Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 346. Netherlands Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 347. Netherlands Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 348. Netherlands Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 349. Netherlands Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 350. Rest of Europe Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 351. Rest of Europe Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 352. Rest of Europe Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 353. Rest of Europe Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 354. Rest of Europe Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 355. Rest of Europe Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 356. MEA Brain Tumor Diagnosis and Treatments, by Country USD Million (2022-2027)
  • Table 357. MEA Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 358. MEA Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 359. MEA Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 360. MEA Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 361. MEA Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 362. MEA Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 363. Middle East Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 364. Middle East Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 365. Middle East Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 366. Middle East Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 367. Middle East Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 368. Middle East Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 369. Africa Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 370. Africa Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 371. Africa Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 372. Africa Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 373. Africa Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 374. Africa Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 375. North America Brain Tumor Diagnosis and Treatments, by Country USD Million (2022-2027)
  • Table 376. North America Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 377. North America Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 378. North America Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 379. North America Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 380. North America Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 381. North America Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 382. United States Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 383. United States Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 384. United States Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 385. United States Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 386. United States Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 387. United States Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 388. Canada Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 389. Canada Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 390. Canada Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 391. Canada Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 392. Canada Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 393. Canada Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 394. Mexico Brain Tumor Diagnosis and Treatments, by Type USD Million (2022-2027)
  • Table 395. Mexico Brain Tumor Diagnosis and Treatments, by Application USD Million (2022-2027)
  • Table 396. Mexico Brain Tumor Diagnosis and Treatments, by Drug Type USD Million (2022-2027)
  • Table 397. Mexico Brain Tumor Diagnosis and Treatments, by Diagnosis Testing USD Million (2022-2027)
  • Table 398. Mexico Brain Tumor Diagnosis and Treatments, by Treatment Type USD Million (2022-2027)
  • Table 399. Mexico Brain Tumor Diagnosis and Treatments, by Type of Brain Tumor USD Million (2022-2027)
  • Table 400. Research Programs/Design for This Report
  • Table 401. Key Data Information from Secondary Sources
  • Table 402. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Brain Tumor Diagnosis and Treatments: by Type USD Million (2016-2021)
  • Figure 5. Global Brain Tumor Diagnosis and Treatments: by Application USD Million (2016-2021)
  • Figure 6. Global Brain Tumor Diagnosis and Treatments: by Drug Type USD Million (2016-2021)
  • Figure 7. Global Brain Tumor Diagnosis and Treatments: by Diagnosis Testing USD Million (2016-2021)
  • Figure 8. Global Brain Tumor Diagnosis and Treatments: by Treatment Type USD Million (2016-2021)
  • Figure 9. Global Brain Tumor Diagnosis and Treatments: by Type of Brain Tumor USD Million (2016-2021)
  • Figure 10. South America Brain Tumor Diagnosis and Treatments Share (%), by Country
  • Figure 11. Asia Pacific Brain Tumor Diagnosis and Treatments Share (%), by Country
  • Figure 12. Europe Brain Tumor Diagnosis and Treatments Share (%), by Country
  • Figure 13. MEA Brain Tumor Diagnosis and Treatments Share (%), by Country
  • Figure 14. North America Brain Tumor Diagnosis and Treatments Share (%), by Country
  • Figure 15. Global Brain Tumor Diagnosis and Treatments share by Players 2021 (%)
  • Figure 16. Global Brain Tumor Diagnosis and Treatments share by Players (Top 3) 2021(%)
  • Figure 17. Global Brain Tumor Diagnosis and Treatments share by Players (Top 5) 2021(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. AstraZeneca (United Kingdom) Revenue: by Geography 2021
  • Figure 21. Carestream Health (United States) Revenue, Net Income and Gross profit
  • Figure 22. Carestream Health (United States) Revenue: by Geography 2021
  • Figure 23. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 24. GE Healthcare (United States) Revenue: by Geography 2021
  • Figure 25. Hitachi, Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 26. Hitachi, Ltd. (Japan) Revenue: by Geography 2021
  • Figure 27. Merck KGaA (United States) Revenue, Net Income and Gross profit
  • Figure 28. Merck KGaA (United States) Revenue: by Geography 2021
  • Figure 29. Koninklijke Philips N.V (Netherlands) Revenue, Net Income and Gross profit
  • Figure 30. Koninklijke Philips N.V (Netherlands) Revenue: by Geography 2021
  • Figure 31. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Pfizer, Inc. (United States) Revenue: by Geography 2021
  • Figure 33. Shimadzu Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 34. Shimadzu Corporation (Japan) Revenue: by Geography 2021
  • Figure 35. Siemens Healthineers (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Siemens Healthineers (Germany) Revenue: by Geography 2021
  • Figure 37. Dr. Reddy’s Laboratories Ltd (India) Revenue, Net Income and Gross profit
  • Figure 38. Dr. Reddy’s Laboratories Ltd (India) Revenue: by Geography 2021
  • Figure 39. ITeos Therapeutics SA (Belgium) Revenue, Net Income and Gross profit
  • Figure 40. ITeos Therapeutics SA (Belgium) Revenue: by Geography 2021
  • Figure 41. Global Brain Tumor Diagnosis and Treatments: by Type USD Million (2022-2027)
  • Figure 42. Global Brain Tumor Diagnosis and Treatments: by Application USD Million (2022-2027)
  • Figure 43. Global Brain Tumor Diagnosis and Treatments: by Drug Type USD Million (2022-2027)
  • Figure 44. Global Brain Tumor Diagnosis and Treatments: by Diagnosis Testing USD Million (2022-2027)
  • Figure 45. Global Brain Tumor Diagnosis and Treatments: by Treatment Type USD Million (2022-2027)
  • Figure 46. Global Brain Tumor Diagnosis and Treatments: by Type of Brain Tumor USD Million (2022-2027)
  • Figure 47. South America Brain Tumor Diagnosis and Treatments Share (%), by Country
  • Figure 48. Asia Pacific Brain Tumor Diagnosis and Treatments Share (%), by Country
  • Figure 49. Europe Brain Tumor Diagnosis and Treatments Share (%), by Country
  • Figure 50. MEA Brain Tumor Diagnosis and Treatments Share (%), by Country
  • Figure 51. North America Brain Tumor Diagnosis and Treatments Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AstraZeneca (United Kingdom)
  • Carestream Health (United States)
  • GE Healthcare (United States)
  • Hitachi, Ltd. (Japan)
  • Merck KGaA (United States)
  • Koninklijke Philips N.V (Netherlands)
  • Pfizer, Inc. (United States)
  • Shimadzu Corporation (Japan)
  • Siemens Healthineers (Germany)
  • Dr. Reddy’s Laboratories Ltd (India)
  • iTeos Therapeutics SA (Belgium)
Additional players considered in the study are as follows:
Mankind Pharmaceuticals (India) , Macleods Pharmaceuticals Ltd.(India) , Canon Medical Systems Corporation (Japan)
Select User Access Type

Key Highlights of Report


May 2022 134 Pages 53 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Brain Tumor Diagnosis and Treatments Market Quantitative research analysis
Global Brain Tumor Diagnosis and Treatments Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Brain Tumor Diagnosis and Treatments market are AstraZeneca (United Kingdom), Carestream Health (United States), GE Healthcare (United States), Hitachi, Ltd. (Japan), Merck KGaA (United States), Koninklijke Philips N.V (Netherlands), Pfizer, Inc. (United States), Shimadzu Corporation (Japan), Siemens Healthineers (Germany), Dr. Reddy’s Laboratories Ltd (India) and iTeos Therapeutics SA (Belgium), to name a few.
North America is dominating the Brain Tumor Diagnosis and Treatments Market.
"Effective Drug Discovery & Patient selection, trial end-point analyses, and the Different Trial Parameters" is seen as one of major challenge by many Industry Players of Brain Tumor Diagnosis and Treatments Market
The Brain Tumor Diagnosis and Treatments market is expected to see a CAGR of 8.65% during projected year 2021 to 2027.

Know More About Global Brain Tumor Diagnosis and Treatments Market Report?

Have a Query? Click Here

Other Related Reports

Tuberculosis Treatment Drugs Comprehensive Study by Type (Active TB, Latent TB), Application (Hospital, Clinic, Durgstore), Drugs (First Line anti-TB Drugs, Second Line anti- TB Drugs) Players and Re...
$ 3500
Acute Disease Comprehensive Study by Type (Acute minor illness (self-limiting), Acute major illness (self-limiting or requiring treatment), Acute presentation of existing major illness (acute exacerb...
$ 3650
Bone Growth Stimulator Comprehensive Study by Application (Spinal Fusion, Delay Union & Non-union Bone Fracture, Oral-maxillofacial, Other Applications), Stimulators (Internal Bone Growth Stimulators...
$ 3750
Cancer Therapeutics Comprehensive Study by Application (Blood cancer, Breast cancer, Lung cancer, Colorectal cancer, Prostate cancer, Other), Drug Selling (Revlimid, Avastin, Herceptin, Rituxan, Opdi...
$ 3800
Gaucher Disease Treatment Comprehensive Study by Therapy (Enzyme Replacement Therapy (Imiglucerase (Cerezyme), Velaglucerase alfa (VPRIV),Taliglucerase alfa (Elelyso), Others, Substrate Replacement T...
$ 3750
Post-Traumatic Stress Disorder Therapeutics Comprehensive Study by End-Users (Male, Female, Children), Drug Class (Antidepressants, Anti-anxiety Drugs, Other Drug Class) Players and Region - Global M...
$ 3500